Consumer Report looks at how "sweetheart deals and patent extensions keep lower-cost generic drugs from consumers." The story lists several approaches that both generic manufacturers and brand-name companies have used to gain and keep market exclusivity. These include: "sneaking patent-existing riders into complex and unrelated legislative procedures; paying chemical supply houses not to sell needed ingredients to rival drug manufacturers; paying competitors to stay out of the market; filing unfounded "citizen petitions" and patents to delay the marketing of a generic drug." The reporter points to specific examples of how pharmaceutical companies have taken advantage of loopholes in current law.
This file is not available for digital download. IRE members may place an order by emailing email@example.com